第4届圣加仑EORTC胃肠道肿瘤会议:胃、交界部及食管腺癌多模式原发治疗中的争议问题
多学科专家小组在 moderated 共识会议上综述了胃、食管及食管胃交界部(AEG)局限期腺癌的多模式原发治疗,报告了讨论要点与推荐。治疗决策以白光内镜联合CT定义肿瘤位置和范围为基础,额外内镜超声主要推荐用于下段AEG(Siewert II和III型)及内镜切除前早期癌,腹腔镜诊断腹膜受累被认为在新辅助治疗前必要。共识认为氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛联合方案是适合患者的新标准化疗方案。
要点
- 白光内镜联合CT定义肿瘤位置和范围是任何治疗决策的骨干。
- 额外内镜超声主要推荐用于下段AEG(Siewert II和III型)及内镜切除前早期癌。
- 腹腔镜诊断腹膜受累被认为在新辅助治疗前对所有胃癌及AEG II和III型必要。
核心结论
- 任何治疗决策都需要在综合多学科环境中进行跨学科讨论。
- 围手术期多模式治疗被建议用于所有局部晚期食管肿瘤和临床分期高于T1N0的胃癌。
- 氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛联合方案是适合患者的新标准化疗方案。
- 围手术期化疗与术前放化疗之间的最佳选择,尤其是对AEG,被确定为开放问题。
研究设计与样本
- 多学科专家小组在 moderated 共识会议上综述了胃、食管及食管胃交界部(AEG)局限期腺癌的多模式原发治疗。
- 本文报告了讨论要点和由此产生的推荐。
主要发现
- 白光内镜联合CT扫描定义肿瘤位置和范围是任何治疗决策的骨干。
- 白光内镜联合CT对浸润深度、淋巴结受累和腹膜受累的价值有限。
- 额外内镜超声主要推荐用于下段食管胃交界部肿瘤(即Siewert II和III型AEG)及内镜切除前早期癌。
- 腹腔镜诊断腹膜受累被认为在新辅助治疗开始前对所有胃癌及AEG II和III型必要。
- 围手术期多模式治疗被建议用于所有局部晚期食管肿瘤和临床分期高于T1N0的胃癌。
关键数值与推荐
- 专家治疗推荐取决于肿瘤位置、生物学、不完全(R1)切除风险、治疗反应、局部或全身复发风险、预测围手术期发病率和患者合并症。
- 共识认为氟尿嘧啶、亚叶酸、奥沙利铂和多西他赛联合方案是适合患者的新标准化疗方案。
临床怎么用
- 任何治疗决策都需要在综合多学科环境中进行跨学科讨论。
- 专家治疗推荐取决于肿瘤位置、生物学、不完全(R1)切除风险、治疗反应、局部或全身复发风险、预测围手术期发病率和患者合并症。
局限性
- 围手术期化疗与术前放化疗之间的最佳选择,尤其是对AEG,被确定为开放问题。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Multimodal primary treatment of localised adenocarcinoma of the stomach, the oesophagus and the oesophagogastric junction (AEG) was reviewed by a multidisciplinary expert panel in a moderated consensus session. Here, we report the key points of the discussion and the resulting recommendations. The exact definition of the tumour location and extent by white light endoscopy in conjunction with computed tomography scans is the backbone for any treatment decision. Their value is limited with respect to the infiltration depth, lymph node involvement and peritoneal involvement. Additional endoscopic ultrasound was recommended mainly for tumours of the lower oesophagogastric junction (i.e. AEG type II and III according to Siewert) and in early cancers before endoscopic resection. Laparoscopy to diagnose peritoneal involvement was thought to be necessary before the start of neoadjuvant treatment in all gastric cancers and in AEG type II and III. In general, perioperative multimodal treatment was suggested for all locally advanced oesophageal tumours and for gastric cancers with a clinical stage above T1N0. There was consensus that the combination of fluorouracil, folinic acid, oxaliplatin and docetaxel is now a new standard chemotherapy (CTx) regimen for fit patients. In contrast, the optimal choice of perioperative CTx versus neoadjuvant radiochemotherapy (neoRCTx), especially for AEG, was identified as an open question. Expert treatment recommendations depend on the tumour location, biology, the risk of incomplete (R1) resection, response to treatment, local or systemic recurrence risks, the predicted perioperative morbidity and patients' comorbidities. In summary, any treatment decision requires an interdisciplinary discussion in a comprehensive multidisciplinary setting.
引用
- Lutz MP, Zalcberg JR, Ducreux M, et al. The 4th St. Gallen EORTC Gastrointestinal Cancer Conference: Controversial issues in the multimodal primary treatment of gastric, junctional and oesophageal adenocarcinoma. Eur J Cancer. 2019. PMID: 30878666. doi:10.1016/j.ejca.2019.01.106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。